NEW YORK, Jan 8 – Qiagen Genomics and Genomics Collaborative have formed a collaboration to compare genetic profiles of patients who have poor reactions to drugs to those with no reported adverse events to metabolic enzymes, the companies announced Monday.
The companies expect to complete the project, in which Qiagen will provide its SNP genotyping services and Genomics Collaborative will offer its database of genetic samples, sometime this spring, the companies said. The companies plan to submit the results of the analysis for publication.
" We believe that drug companies will save costs and reduce the time associated with developing new drugs by having access to patient profiles that can predict individual patient response with regards to drug absorption, distribution, metabolism and excretion outcomes," William Hirschman, GCI's Vice President for Business Development, said in a statement.
The companies said their project is the “most extensive study of its kind ever conducted."